Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction
- Thompson, Alexander J.
- Fellay, Jacques
- Patel, Keyur
- Tillmann, Hans L.
- Naggie, Susanna
- Ge, Dongliang
- Urban, Thomas J.
- Shianna, Kevin V.
- Muir, Andrew J.
- Fried, Michael W.
- Afdhal, Nezam H.
- Goldstein, David B.
- McHutchison, John G.
Publication date
January 2010
DOIAbstract
In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4
Add to ORKG